Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05868486
Other study ID # 21574
Secondary ID NCI-2022-0182921
Status Active, not recruiting
Phase Early Phase 1
First received
Last updated
Start date May 20, 2022
Est. completion date July 20, 2024

Study information

Verified date March 2024
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates patient acceptability of whole body magnetic resonance imaging (WBM) and liquid biopsies (LB) in detecting early stage cancer in patients with a strong family history of cancer. Collecting family history and testing for genes passed on from parent to child (germline testing) can be used to predict the likelihood of a patient developing cancer. Currently, detection of early cancers focuses on screening specific organ systems such as breast and colon cancer. Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside the body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to cancer. Liquid biopsy is test that analyzes blood samples to determine if cancer cells are present. This study may help researchers determine the feasibility of WBM and liquid biopsies to detect early stage cancer in patients that have a strong family history of cancer.


Description:

PRIMARY OBJECTIVE: I. To assess the acceptability of the approach of LB and WBM. SECONDARY OBJECTIVES: I. Determine the prevalence of WBM findings requiring additional imaging or invasive testing. II. Determine the effect of germline testing, LB, and WBM on psychological distress and health-related quality of life (HR-QOL) at 6 months after testing compared with baseline. EXPLORATORY OBJECTIVE: I. Determine correlation between high-risk LB findings and cancer detected on WBM. OUTLINE: This is an observational study. Patients undergo WBM without contrast, blood sample collection for liquid biopsy, and complete surveys on study. Germline testing may also be performed on blood sample collected as standard of care or using the Precision Medicine protocol (Institutional Review Board [IRB] 96144).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 100
Est. completion date July 20, 2024
Est. primary completion date July 20, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age >= 50 years, or age within 10 years of first degree relative with cancer at age of diagnosis (as long as age is >= 18) - Have a strong family history of cancer ( >= 2 first-degree relatives with cancer, one first and second degree relative with cancer in one lineage (side of family), or at least three first or second degree relatives with cancer in one lineage (side of the family). Non-melanoma skin cancer excluded from family history eligibility - Have a family history of early-onset cancer (age >40) in at least one first-degree relative - Willing to have 50 mL of blood (approximately 3.5 tablespoons) drawn (40 ml if germline testing already performed) - Able to undergo MRI (no implants, metal, or claustrophobia that would preclude MRI) - Any cancer diagnosis within past 5 years, excluding non-melanoma skin cancer - Positron emission tomography/computed tomography (PET/CT) or other whole body imaging modality (including combination of CT chest and abdomen) within 3 years - No signs/symptoms of possible cancer (e.g. hemoptysis, breast mass, blood per rectum, unexplained weight loss) - Willing to undergo standard of care genetic counseling and germline testing, or has already undergone genetic counseling and germline testing - Documented informed consent of the participant Exclusion Criteria: - Unable to provide informed consent - Contraindications to MRI (implants, metal, or claustrophobia that would preclude MRI)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Biospecimen Collection
Undergo blood sample collection
Genetic:
Genetic Testing for Cancer Risk
Undergo germline testing
Procedure:
Liquid Biopsy
Undergo liquid biopsy testing
Magnetic Resonance Imaging of the Whole Body without Contrast
Undergo whole body MRI without contrast
Other:
Survey Administration
Complete surveys

Locations

Country Name City State
United States City of Hope Medical Center Duarte California

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation between high-risk liquid biopsy findings and cancer detected on WBM Liquid biopsy (LB) test sensitivity and specificity calculated by comparing the LB results with the WBM results, with WBM results considered the gold standard. Confusion matrix statistics, such as positive predictive value, negative predictive value, and test accuracy examined. Results reported with their corresponding 95% confidence intervals. Up to 6 months after WBM
Primary Acceptability of germline testing, liquid biopsy and whole body magnetic resonance imaging (WBM) Acceptability, as measured by the survey question "How satisfied are you with the research study overall?" and is defined as a score of 4 ("moderately acceptable) or 5 ("highly acceptable"). Up to 6 months after WBM
Secondary Prevalence of WBM findings requiring additional imaging or invasive testing Prevalence of WBM findings requiring additional imaging or invasive testing, described as a per participant percentage. Up to 6 months after WBM
Secondary Psychological distress (Germline testing)A The effect of germline testing on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Psychological distress (Germline testing)B The effect of germline testing on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Psychological distress (Liquid Biopsy)A The effect of LB on psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Psychological distress (Liquid Biopsy)B The effect of LB on psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Psychological distress (WBM)A The effect of Whole Body MRI on Psychological distress, as measured by STAI survey composite score between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Psychological distress (WBM)B The effect of Whole Body MRI on Psychological distress, as measured by cancer worry scale survey scores between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Health Related Quality of Life (HRQOL/Germline) The effect of germline testing on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Health Related Quality of Life (HRQOL/LB) The effect of LB on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. Up to 6 months after WBM
Secondary Health Related Quality of Life (HRQOL/WBM) The effect of WBM on HRQOL, as measured by the change in SF12 survey composite score between baseline and 6 months after testing. Up to 6 months after WBM
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A